Karyopharm Therapeutics Analyst Ratings
Karyopharm Therapeutics Analyst Ratings
Karyopharm Therapeutics 分析
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 144.65% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/03/2023 | 328.13% | Piper Sandler | $8 → $7 | Maintains | Overweight |
| 08/03/2023 | 144.65% | RBC Capital | $5 → $4 | Maintains | Outperform |
| 08/03/2023 | 511.62% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 07/26/2023 | 144.65% | Wedbush | $7 → $4 | Maintains | Neutral |
| 07/26/2023 | 511.62% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 07/18/2023 | 511.62% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/05/2023 | 205.81% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 05/05/2023 | 511.62% | HC Wainwright & Co. | $16 → $10 | Maintains | Buy |
| 05/05/2023 | 511.62% | Baird | $14 → $10 | Maintains | Outperform |
| 04/19/2023 | 878.59% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 02/22/2023 | 878.59% | HC Wainwright & Co. | → $16 | Maintains | Buy |
| 02/16/2023 | 878.59% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 01/27/2023 | 205.81% | Morgan Stanley | $7 → $5 | Maintains | Equal-Weight |
| 01/19/2023 | 389.3% | Piper Sandler | → $8 | Initiates Coverage On | → Overweight |
| 01/10/2023 | 878.59% | HC Wainwright & Co. | $18 → $16 | Maintains | Buy |
| 01/10/2023 | 205.81% | SVB Leerink | $6 → $5 | Maintains | Market Perform |
| 11/04/2022 | 511.62% | RBC Capital | $7 → $10 | Upgrades | Sector Perform → Outperform |
| 11/04/2022 | 266.97% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
| 09/09/2022 | 328.13% | Morgan Stanley | $10 → $7 | Maintains | Equal-Weight |
| 08/05/2022 | 1000.92% | HC Wainwright & Co. | $21 → $18 | Maintains | Buy |
| 08/05/2022 | 756.27% | Baird | $17 → $14 | Maintains | Outperform |
| 08/05/2022 | 389.3% | Barclays | $14 → $8 | Maintains | Overweight |
| 05/05/2022 | 205.81% | SVB Leerink | $6 → $5 | Maintains | Market Perform |
| 03/18/2022 | 1245.57% | HC Wainwright & Co. | $23 → $22 | Maintains | Buy |
| 03/08/2022 | 389.3% | RBC Capital | $12 → $8 | Maintains | Sector Perform |
| 03/02/2022 | 266.97% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 02/09/2022 | 389.3% | JP Morgan | → $8 | Upgrades | Underweight → Neutral |
| 01/10/2022 | 389.3% | SVB Leerink | $6 → $8 | Maintains | Market Perform |
| 12/09/2021 | 450.46% | RBC Capital | $8 → $9 | Maintains | Sector Perform |
| 11/19/2021 | 511.62% | Morgan Stanley | $27 → $10 | Downgrades | Overweight → Equal-Weight |
| 10/12/2021 | 1551.38% | Morgan Stanley | $29 → $27 | Maintains | Overweight |
| 08/06/2021 | 1490.21% | HC Wainwright & Co. | $49 → $26 | Maintains | Buy |
| 08/06/2021 | 266.97% | SVB Leerink | → $6 | Downgrades | Outperform → Market Perform |
| 08/06/2021 | 389.3% | RBC Capital | $17 → $8 | Downgrades | Outperform → Sector Perform |
| 08/06/2021 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 05/03/2021 | 817.43% | SVB Leerink | $22 → $15 | Maintains | Outperform |
| 02/11/2021 | 1245.57% | SVB Leerink | $25 → $22 | Maintains | Outperform |
| 01/12/2021 | 1429.05% | SVB Leerink | $29 → $25 | Maintains | Outperform |
| 11/03/2020 | 1857.19% | Morgan Stanley | $34 → $32 | Maintains | Overweight |
| 11/03/2020 | 1612.54% | SVB Leerink | $30 → $28 | Maintains | Outperform |
| 08/04/2020 | 1734.86% | SVB Leerink | $31 → $30 | Maintains | Outperform |
| 07/02/2020 | 1979.51% | Morgan Stanley | → $34 | Initiates Coverage On | → Overweight |
| 06/23/2020 | 1490.21% | Wedbush | $25 → $26 | Maintains | Neutral |
| 06/23/2020 | 2407.65% | HC Wainwright & Co. | $40 → $41 | Maintains | Buy |
| 05/06/2020 | 2346.48% | HC Wainwright & Co. | $43 → $40 | Maintains | Buy |
| 05/05/2020 | 1673.7% | SVB Leerink | $30 → $29 | Maintains | Outperform |
| 03/04/2020 | 1734.86% | Barclays | → $30 | Initiates Coverage On | → Overweight |
| 03/02/2020 | 2529.97% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 01/17/2020 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 01/14/2020 | 2163% | HC Wainwright & Co. | $36 → $37 | Reiterates | → Buy |
| 11/05/2019 | 1000.92% | Canaccord Genuity | $15 → $18 | Maintains | Buy |
| 11/05/2019 | 2101.83% | HC Wainwright & Co. | $32 → $36 | Maintains | Buy |
| 07/23/2019 | 878.59% | JP Morgan | $8 → $16 | Upgrades | Neutral → Overweight |
| 03/01/2019 | 328.13% | JP Morgan | $21 → $7 | Downgrades | Overweight → Neutral |
| 02/27/2019 | 266.97% | Wedbush | $14 → $6 | Maintains | Outperform |
| 02/27/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 01/03/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 11/09/2018 | — | Wedbush | Upgrades | Neutral → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/07/2023 | 144.65% | 摩根士丹利 | $5→$4 | 維護 | 等重 |
| 08/03/2023 | 328.13% | 派珀·桑德勒 | $8→$7 | 維護 | 超重 |
| 08/03/2023 | 144.65% | 加拿大皇家銀行資本 | $5→$4 | 維護 | 跑贏大盤 |
| 08/03/2023 | 511.62% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 07/26/2023 | 144.65% | 韋德布什 | $7→$4 | 維護 | 中性 |
| 07/26/2023 | 511.62% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 07/18/2023 | 511.62% | HC Wainwright公司 | →$10 | 重申 | 購買→購買 |
| 05/05/2023 | 205.81% | 加拿大皇家銀行資本 | $6→$5 | 維護 | 跑贏大盤 |
| 05/05/2023 | 511.62% | HC Wainwright公司 | $16→$10 | 維護 | 買 |
| 05/05/2023 | 511.62% | 貝爾德 | $14→$10 | 維護 | 跑贏大盤 |
| 04/19/2023 | 878.59% | HC Wainwright公司 | →$16 | 重申 | →購買 |
| 02/22/2023 | 878.59% | HC Wainwright公司 | →$16 | 維護 | 買 |
| 02/16/2023 | 878.59% | HC Wainwright公司 | →$16 | 重申 | →購買 |
| 2023年1月27日 | 205.81% | 摩根士丹利 | $7→$5 | 維護 | 等重 |
| 2023年1月19日 | 389.3% | 派珀·桑德勒 | →$8 | 開始承保 | →超重 |
| 2023年1月10日 | 878.59% | HC Wainwright公司 | $18→$16 | 維護 | 買 |
| 2023年1月10日 | 205.81% | SVB Leerink | $6→$5 | 維護 | 市場表現 |
| 11/04/2022 | 511.62% | 加拿大皇家銀行資本 | $7→$10 | 升級 | 行業表現優於→ |
| 11/04/2022 | 266.97% | SVB Leerink | $5→$6 | 維護 | 市場表現 |
| 09/09/2022 | 328.13% | 摩根士丹利 | $10→$7 | 維護 | 等重 |
| 08/05/2022 | 1000.92% | HC Wainwright公司 | $21→$18 | 維護 | 買 |
| 08/05/2022 | 756.27% | 貝爾德 | $17→$14 | 維護 | 跑贏大盤 |
| 08/05/2022 | 389.3% | 巴克萊 | $14→$8 | 維護 | 超重 |
| 05/05/2022 | 205.81% | SVB Leerink | $6→$5 | 維護 | 市場表現 |
| 03/18/2022 | 1245.57% | HC Wainwright公司 | $23→$22 | 維護 | 買 |
| 03/08/2022 | 389.3% | 加拿大皇家銀行資本 | $12→$8 | 維護 | 行業表現 |
| 03/02/2022 | 266.97% | SVB Leerink | $8→$6 | 維護 | 市場表現 |
| 02/09/2022 | 389.3% | 摩根大通 | →$8 | 升級 | 減重→中性 |
| 2022年1月10日 | 389.3% | SVB Leerink | $6→$8 | 維護 | 市場表現 |
| 12/09/2021 | 450.46% | 加拿大皇家銀行資本 | $8→$9 | 維護 | 行業表現 |
| 2021年11月19日 | 511.62% | 摩根士丹利 | $27→$10 | 評級下調 | 超重→等重 |
| 10/12/2021 | 1551.38% | 摩根士丹利 | $29→$27 | 維護 | 超重 |
| 08/06/2021 | 1490.21% | HC Wainwright公司 | $49→$26 | 維護 | 買 |
| 08/06/2021 | 266.97% | SVB Leerink | →$6 | 評級下調 | 跑贏→市場表現 |
| 08/06/2021 | 389.3% | 加拿大皇家銀行資本 | $17→$8 | 評級下調 | 跑贏→板塊表現 |
| 08/06/2021 | - | 摩根大通 | 評級下調 | 增持→減持 | |
| 05/03/2021 | 817.43% | SVB Leerink | $22→$15 | 維護 | 跑贏大盤 |
| 02/11/2021 | 1245.57% | SVB Leerink | $25→$22 | 維護 | 跑贏大盤 |
| 2021/12/01 | 1429.05% | SVB Leerink | $29→$25 | 維護 | 跑贏大盤 |
| 11/03/2020 | 1857.19% | 摩根士丹利 | $34→$32 | 維護 | 超重 |
| 11/03/2020 | 1612.54% | SVB Leerink | $30→$28 | 維護 | 跑贏大盤 |
| 08/04/2020 | 1734.86% | SVB Leerink | $31→$30 | 維護 | 跑贏大盤 |
| 07/02/2020 | 1979.51% | 摩根士丹利 | →$34 | 開始承保 | →超重 |
| 2020/06/23 | 1490.21% | 韋德布什 | $25→$26 | 維護 | 中性 |
| 2020/06/23 | 2407.65% | HC Wainwright公司 | $40→$41 | 維護 | 買 |
| 05/06/2020 | 2346.48% | HC Wainwright公司 | $43→$40 | 維護 | 買 |
| 05/05/2020 | 1673.7% | SVB Leerink | $30→$29 | 維護 | 跑贏大盤 |
| 03/04/2020 | 1734.86% | 巴克萊 | →$30 | 開始承保 | →超重 |
| 03/02/2020 | 2529.97% | HC Wainwright公司 | $40→$43 | 維護 | 買 |
| 2020/01/17 | - | 韋德布什 | 評級下調 | 跑贏→中性 | |
| 2020/01/14 | 2163% | HC Wainwright公司 | $36→$37 | 重申 | →購買 |
| 2019年11月05日 | 1000.92% | 卡納科特·格納奇 | $15→$18 | 維護 | 買 |
| 2019年11月05日 | 2101.83% | HC Wainwright公司 | $32→$36 | 維護 | 買 |
| 2019年07月23日 | 878.59% | 摩根大通 | $8→$16 | 升級 | 中性→超重 |
| 2019年03月01日 | 328.13% | 摩根大通 | $21→$7 | 評級下調 | 超重→中性 |
| 2019年02月27日 | 266.97% | 韋德布什 | $14→$6 | 維護 | 跑贏大盤 |
| 2019年02月27日 | - | B of A證券 | 評級下調 | 中性→表現不佳 | |
| 2019年03月01日 | - | B of A證券 | 升級 | 表現不佳的→中性 | |
| 2018/09/11 | - | 韋德布什 | 升級 | 中性→表現優異 |
What is the target price for Karyopharm Therapeutics (KPTI)?
卡拉帕姆治療公司(KPTI)的目標價格是多少？
The latest price target for Karyopharm Therapeutics (NASDAQ: KPTI) was reported by Morgan Stanley on August 7, 2023. The analyst firm set a price target for $4.00 expecting KPTI to rise to within 12 months (a possible 144.65% upside). 20 analyst firms have reported ratings in the last year.
納斯達克(納斯達克代碼：KPTI)的最新目標價是由摩根士丹利於2023年8月7日報道的。這家分析公司將目標價定為4美元，預計KPTI將在12個月內升至(可能上漲144.65)。去年，已有20家分析公司公佈了評級。
What is the most recent analyst rating for Karyopharm Therapeutics (KPTI)?
卡拉帕姆治療公司(KPTI)的最新分析師評級是多少？
The latest analyst rating for Karyopharm Therapeutics (NASDAQ: KPTI) was provided by Morgan Stanley, and Karyopharm Therapeutics maintained their equal-weight rating.
納斯達克(Sequoia Capital：KPTI)的最新分析師評級由摩根士丹利提供，卡拉帕姆治療公司維持其同等權重評級。
When is the next analyst rating going to be posted or updated for Karyopharm Therapeutics (KPTI)?
卡拉帕姆治療公司(KPTI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karyopharm Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karyopharm Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師們在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與卡裡奧帕姆治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Karyopharm治療公司的上一次評級是在2023年8月7日提交的，所以你應該預計下一次評級將在2024年8月7日左右的某個時候提供。
Is the Analyst Rating Karyopharm Therapeutics (KPTI) correct?
分析師對卡拉帕姆治療公司(KPTI)的評級正確嗎？
While ratings are subjective and will change, the latest Karyopharm Therapeutics (KPTI) rating was a maintained with a price target of $5.00 to $4.00. The current price Karyopharm Therapeutics (KPTI) is trading at is $1.64, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Karyopamm治療公司(KPTI)評級保持不變，目標價在5.00美元至4.00美元之間。卡裡奧帕姆治療公司(KPTI)目前的交易價格為1.64美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。